The Clinical Management Of Early Alzheimer S Disease

The enormous human and economic toll of Alzheimer's Disease in societies in which more and more people are living into old age is well-recognized. Scientists and practitioners alike have been working to limit it. Their major focus has been patients in the later stages of the disease, when dementia is fully established. Yet patients in the early stages of cognitive decline, far more numerous, often still living independently with family members, present a bewildering variety of challenges. Bringing together leading authors with diverse expertise, this Handbook offers the first comprehensive overview of approaches to the management of early-stage issues. The authors summarize the important implications of the latest research in their own fields for: * the recognition and formal diagnosis of cognitive problems; * the assessment of specific difficulties in daily functioning; * the formulation of a management plan integrating pharmacological, neuropsychological, behavioral, and cognitive strategies; and * the facilitation and support of caregivers' efforts. All professionals involved in any way with the care of early Alzheimer's patients and their families will find this book an indispensable reference.

New edition, completely rewritten, with new chapters on endovascular surgery and mitochrondrial and ion channel disorders.

Nearly 44 million people have Alzheimer’s or related dementia worldwide, according to the Alzheimer’s Disease International organization. That number is expected to double every 20 years. Unlike other books on the market, Alzheimer's Disease: Understanding Biomarkers, Big Data, and Therapy covers recent advancements in cognitive, clinical, neural, and therapeutic aspects of Alzheimer’s and other forms of dementia. First, readers are introduced to cognitive and clinical studies, focusing on the different types of memory impairment, past and future thinking. This includes the prevalence of depression, its relationship to other symptoms, and the quality of life for those with Alzheimer’s disease. In addition, the book discusses recent studies on memory dysfunction in advanced-stage Alzheimer’s disease, in comparison to early-stage, including a chapter on the underlying factors in the transition from mild cognitive impairment to Alzheimer’s diagnosis. Following this section, the book presents recent studies on the role of different cortical and subcortical structures in the development of various symptoms in Alzheimer’s disease, as well as different neural biomarkers underlying the development and treatment of the disease. In the last section of the book, therapeutic aspects of Alzheimer’s disease, focusing on behavioral and pharmacological treatments of sleep disorders, memory problems, and depression, are reviewed. The book aids readers in understanding the advances in research and care, making it a prime tool for all clinicians, psychologists, researchers, neurologists, and caregivers of dementia patients. Reviews recent developments of cognitive and clinical studies Covers factors underlying the transition from mild cognitive impairment to Alzheimer’s disease Discusses different neural biomarkers underlying the development and treatment of Alzheimer’s disease Provides a comparison of the effectiveness of various types of treatments

A problem-solving book that focuses on practical approaches to providing ongoing care for Alzheimer's patients in the areas of nursing, occupational therapy, social work, dentistry, physical therapy, and recreational therapy.

Alzheimer’s disease (AD) is a devastating and dehumanizing illness affecting increasingly large numbers of elderly and even middle-aged persons in a worldwide epidemic. Alzheimer’s Disease: A Physician’s Guide to Practical Management was written by selected clinicians and scientists who represent some of the world’s leading centers of excellence in AD research. The editors are proud and grateful for their profound contributions. This book is particularly designed to assist physicians and other health-care professionals in the evaluation, assessment, and treatment of individuals with AD. At the same time, by illuminating the basic scientific background, we hope to provide state-of-the art information about the disease and possible future therapeutic strategies. The recent psychiatric treatment aspects of AD are also clearly presented. Because the early diagnosis of the dementia process is now considered of increasing importance, we focus particularly in several chapters on early changes and preclinical conditions, such as mild cognitive impairment and predementia AD.

Owing to the success of the first edition and the rapid development of new drugs for treating Alzheimer's disease, Serge Gauthier has approached not only his original contributors but a number of leading clinicians and researchers to give their views based on clinical experience and scientific evidence for the treatment of this disease.

The third edition of this successful textbook has been completely updated throughout and includes new chapters on electrophysiological tests, biological markers, global staging measures, and management of neuropsychiatric symptoms. There has been steady progress in our understanding of the natural history, prognostic factors and treatments for Alzheimer’s disease since the previous edition of this textbook was published in 1999. The chapters deal with the full spectrum of populations at risk, persons in prodromal stages, and patients from mild to severe and even terminal stages. The contributors are opinion leaders from North America and Europe, which gives the book an internationally balanced outlook. This new edition will be essential reading for a wide range of clinical neuroscientists who manage patients with this challenging disease.

This issue of Medical Clinics covers the important advances surrounding the early intervention of Alzheimer's Disease. Guest edited by world-renowned experts from around the world, the topics covered will include evaluation of new diagnostic criteria, CSF biomarkers, diagnostic imaging, neurocognitive approaches, breaking clinical trials and more.